College of Psychiatric and Neurologic Pharmacists

Content

The articles selected by CPNP Recertification Committee for the BCPP Recertification Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline.

Content

The articles selected by CPNP Recertification Committee for the BCPP Recertification Literature Analysis are based on a 7-year curriculum. This curriculum is developed using the Board of Pharmaceutical Specialties' Content Outline for the Psychiatric Pharmacy Specialty Certification Examination as a guideline. Since CPNP became the sole BCPP recertification provider in 2008, the articles are chosen to cover the three content domains - Domain I: Clinical and Therapeutic Management; Domain II: Education and Dissemination of Information; and, Domain III: Clinical Administration.  This course is an application-based educational program designed for pharmacists to analyze and apply information.

The CPNP BCPP Recertification Literature Analysis includes:

• The home-study manual containing the required readings needed to prepare for the online assessment.
• For pharmacists, 10.0 contact hours of ACPE credit and 10.0 contact hours of recertification credit achieved by successfully completing the online CPNP recertification examination.

2012 Literature Analysis Articles

• Anxiety (2 hours)

  Manassis K. Managing anxiety related to anaphylaxis in childhood: A systematic review. J Allergy. Volume 2012, Article ID 316296, doi:10.1155/2012/316296. ACPE: 0.5 contact hour; Application: #0284-0000-12-054-H01-P

  Learning Objectives

  1. Categorize different aspects of anxiety symptoms surrounding anaphylaxis in children and adolescents with anaphylactic conditions.
  2. Compose a plan to manage anxiety in children or adolescents with anaphylactic conditions.

  Rynn M, Puliafico A, Heleniak C, Rikhi P, Ghalib K, Vidair H. Advances in pharmacotherapy for pediatric anxiety disorders.  Depress Anxiety 2011;28:76-87. ACPE: 0.75 contact hour; Application: #0284-0000-12-054-H01-P

  Learning Objectives

  1. Examine evidence-based options for the pharmacotherapy of pediatric anxiety disorders.
  2. Evaluate research supporting efficacy of novel pharmacological therapies for the management of anxiety.
  3. Apply recommendations to current practice of pharmacologic treatment and monitoring of pediatric anxiety disorders.

  Sokolowski CJ, Giovannitti JA, Boynes SG. Needle phobia: Etiology, adverse consequences, and patient management. Dent Clin N Am 2010; 54:731-744. ACPE: 0.75 contact hour; Application: #0284-0000-12-054-H01-P

  Learning Objectives

  1. Describe the prevalence, demographics, and etiologic theories of needle phobia.
  2. Predict the clinical symptoms and physiological changes during venipuncture associated with needle phobia. 
  3. Propose non-pharmacological and pharmacological strategies for the management of avoidance of venipuncture by patients with needle phobia.

• Child and Adolescent (1.5 hours)

  Feucht C, Patel DR. Herbal medicines in pediatric neuropsychiatry. Pediatr Clin N Am 2011;58(1):33-54. ACPE: 1 contact hour; Application: #0284-0000-12-053-H01-P

  Learning Objectives

  1. Characterize the lack of standardization in the field of complementary and alternative medicine and how it poses a challenge to healthcare professionals in determining appropriate use.
  2. Predict potential adverse drug reactions and drug-drug interactions with herbal medicines used in pediatric neuropsychiatry.
  3. Assess the appropriateness of the use of herbal medicines for the treatment of specific mental health issues in pediatric neuropsychiatry based on the level of available evidence.
  4. Design a treatment regimen using herbal medicines for the management of pediatric neuropsychiatric disorders when faced with opposition to the use of allopathic medication.

  Rowles B, Findling R. Review of pharmacotherapy options for the treatment of Attention-Deficit / Hyperactivity Disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Dev Disabil Res Rev 2010;16(3):273-282. ACPE: 0.5 contact hour; Application: #0284-0000-12-053-H01-P

  Learning Objectives

  1. Compare the rates of comorbid ADHD found in various types of developmental disabilities.
  2. Choose a pharmacotherapy option likely to be efficacious for a patient with a specific developmental disability exhibiting ADHD-like symptoms.
  3. Develop a pharmacotherapy treatment plan for a developmentally disabled patient who is to be treated with a specific medication for ADHD symptoms.

• Mood Disorders (2.5 hours)

  Berk  L, Hallam KT, Colom F, et al.  Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol Clin Exp 2010;25:1–16. ACPE: 1 contact hour; Application: #0284-0000-12-051-H01-P

  Learning Objectives

  1. Distinguish between positive and negative risk factors associated with adherence issues in patients with bipolar disorder.
  2. Design an intervention (e.g., psychosocial, psychoeducation, behavioral, etc.) to improve medication adherence in patients with bipolar disorder.
  3. Examine the effects of medication adherence on the course of bipolar disorder.
  4. Apply definitions of the various types of medication adherence present in patients diagnosed with bipolar disorder.

  Ng F, Mammen OK, Wilting I, et al. The International Society of Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord 2009;11:559–595. ACPE: 1.5 contact hour; Application: #0284-0000-12-050-H05-P

  Learning Objectives

  1. Apply the ISBD consensus guidelines for the safety monitoring of bipolar disorder treatments taking into consideration cost.
  2. Distinguish serious adverse events associated with the use of lithium, anticonvulsants, or atypical antipsychotics in patients with bipolar disorder.
  3. Develop a safety monitoring plan for patients with bipolar disorder on lithium, valproic acid, carbamazepine, lamotrigine, or atypical antipsychotics using the ISBD guidelines.
  4. Detect drug interactions with the potential to cause serious adverse events in commonly used medications to manage bipolar disorder.
  5. Design a safety monitoring plan for lithium, anticonvulsants, and atypical antipsychotics when used in children and elderly patients for bipolar disorder.
  6. Outline a safety monitoring plan for the use of lithium, anticonvulsants, and atypical antipsychotics in pregnant women with bipolar disorder.

• Pain and Substance Abuse (1 hour)

  Manchikanti L, Malla Y, Wargo BW, et al. Protocol for accuracy of point of care (POC) or in-office urine drug testing (Immunoassay) in chronic pain patients: A prospective analysis of immunoassay and liquid chromatography tandem mass spectometry (LC/MS/MS). Pain Physician 2010;13(1):E1-E22. ACPE: ½ contact hour; Application: #0284-0000-12-055-H01-P

  Learning Objectives

  1. Assess the clinical significance of urine drug testing used to gauge misuse/abuse of opioids/illicit substances.
  2. Interpret the results of a urine drug screen within the context of a patient case.
  3. Compare the available urine drug testing screens and the utility of each in clinical practice.

  Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain 2010;11(7):602-611. ACPE: ½ hour; Application: #0284-0000-12-050-H05-P

  Learning Objectives

  1. Identify the types of behavior that might denote problem patterns in patients receiving chronic opioid therapy.
  2. Apply universal precautions to determine the appropriate management of patients on chronic opioid therapy.

• Personality Disorders-Borderline  (1 hour)

  Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomized trials. Br J Psychiatry 2010;196:4-12. ACPE: 1 contact hour; Application: #0284-0000-12-055-H01-P

  Learning Objectives

  1. Predict the generalizability of the systematic review results for specific patients based on the main characteristics of included clinical trials.
  2. Evaluate the evidence supporting first- and second-generation antipsychotics, mood stabilizers, antidepressants, and omega-3 fatty acids for efficacy in managing symptoms of borderline personality disorder.
  3. Select a medication for patients with borderline personality disorder who present with specific symptom clusters..
  4. Design a study for medication management of borderline personality disorder that addresses limitations of current studies as identified in this review.

• Schizophrenia (2 hours)

  Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Haan L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade. European Psychiatry 2011,doi:10.1016/j.eurpsy.2011.02.005. ACPE: 1 contact hour; Application: #0284-0000-12-052-H01-P

  Learning Objectives

  1. Detect factors that affect medication adherence in patients with schizophrenia.
  2. Compare the beneficial effects of various interventions to improve medication adherence in patients with schizophrenia. 
  3. Design a care plan to improve medication adherence in patients with schizophrenia.
  4. Develop a recommendation for improvement to a medication adherence enhancement program based on available adherence studies.

  Topiwala A, Fazel S. The pharmacological management of violence in schizophrenia: A structured review. Expert Rev Neurother 2011;11(1):53-63. ACPE: 1 contact hour; Application: #0284-0000-12-052-H01-P

  Learning Objectives

  1. Design the most appropriate pharmacologic treatment strategy to manage violence in a patient with schizophrenia.
  2. Analyze the effectiveness of various treatment options available for managing violence in schizophrenia.
  3. Recommend nonpharmacologic treatment to manage violent behavior for a patient with schizophrenia.
  4. Propose modifications to a study design that will address limitations in existing studies of treatment of violence in patients with schizophrenia.

Requirements

To satisfactorily complete the BCPP Recertification Literature Analysis and receive 10.0 hours of Recertification and ACPE credit, candidates must meet the following requirements:

• Abide by a confidentiality and honesty statement requiring individual completion of the Recertification education.
• Complete an online assessment by the deadline of August 22, 2012.
• Meet the minimum passing score for the examinations as determined by a panel of experts.

Registration

If you wish to purchase Recertification programming, an online payment option is provided. Alternatively, you may print off the registration form and submit the form and payment via fax to CPNP at 888-551-7617.

Statements of Credit

Pharmacists can obtain 10.0 contact hours of ACPE credit and 10.0 hours of recertification credit by successfully completing the online CPNP Literature Analysis examination. The ACPE numbers for this course are pending. This course expires August 22, 2012.

ACPE Statements of Credit will be available online at www.cpnp.org within 6 weeks after the examination deadline. Notification of statement availability will be provided to each registrant via email. A letter confirming BCPP recertification programming successfully completed each year is mailed to each registrant in December. This is followed by CPNP’s report to BPS. BPS updates its records no later than the end of the first quarter of the following year. Visit the CPNP Transcript Center for a detailed listing of all Recertification programming completed (requires log-in into the CPNP website).